Home » Topics » BioWorld Science

BioWorld Science
RSS

Vigil Neuroscience advances TREM2 agonists

Aug. 20, 2021

Persica completes first stage of clinical trial on PP-353 for low back pain

Aug. 20, 2021

Bright Minds Biosciences compound reduces seizures in animal models of Dravet syndrome/epilepsy

Aug. 20, 2021

COM-902 derivative AZD-2936 enters the clinic for non-small cell lung cancer

Aug. 19, 2021

Well Marker Bio starts phase I study of WM-S1-030 for solid tumors

Aug. 19, 2021

"Not just the flu" holds for SARS-CoV-2 long-term effects, too

Aug. 19, 2021

TT-00420 enters phase I/II trial for advanced solid tumors

Aug. 19, 2021

Viral-trapping icosahedral shells devised as broad-spectrum antiviral platform

Aug. 19, 2021

First patient enrolled in trial on sirolimus drug-eluting balloon for erectile dysfunction

Aug. 19, 2021

APVO-436 may benefit patients with AML and MDS, first-in-human data suggest

Aug. 19, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
SERPINB1 as potential biomarker for spinocerebellar ataxia type 2
BioWorld Science
Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...